YM155 induces EGFR suppression in pancreatic cancer cells

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Na, Young Soon ^a   Yang, Soo Jin ^a   Kim, Seung Mi ^a   Jung, Kyung Ah ^a   Moon, Jai Hee ^a   Shin, Jae Sik ^a   Yoon, Dok Hyun ^b   Hong, Yong Sang ^a,b   Ryu, Min Hee ^b   Lee, Jae Lyun ^a,b   Lee, Jung Shin ^a,b   Kim, Tae Won ^a,b  

^a Asan Medical Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN MCL 1; SELUMETINIB; SEPANTRONIUM BROMIDE; STAT1 PROTEIN; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; TUMOR VOLUME; TUMOR XENOGRAFT; UBIQUITINATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; NAPHTHOQUINONES; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEOLYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR; TUMOR BURDEN; UBIQUITINATION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862486402     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038625     Document Type: Article

References (42)

1. Kleespies A, Jauch KW, Bruns CJ, (2006) Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer? Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy 9: 1-18.
2. Altieri DC, (2008) Survivin, cancer networks and pathway-directed drug discovery. Nature reviews Cancer 8: 61-70.
3. Wheatley SP, McNeish IA, (2005) Survivin: a protein with dual roles in mitosis and apoptosis. International review of cytology 247: 35-88.
4. Qiao JG, Zhang YQ, Yin YC, Tan Z, (2004) Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2. World J Gastroenterol 10: 2759-2761.
5. Ryan BM, O'Donovan N, Duffy MJ, (2009) Survivin: a new target for anti-cancer therapy. Cancer treatment reviews 35: 553-562.
6. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, et al. (2011) Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer science 102: 614-621.
7. Iwasa T, Okamoto I, Takezawa K, Yamanaka K, Nakahara T, et al. (2010) Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. British journal of cancer 103: 36-42.
8. Nakahara T, Yamanaka K, Hatakeyama S, Kita A, Takeuchi M, et al. (2011) YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anti-cancer drugs 22: 454-462.
9. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, et al. (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer research 67: 8014-8021.
10. Avraham R, Yarden Y, (2011) Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 12: 104-117.
11. Wheeler DL, Dunn EF, Harari PM, (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7: 493-507.
12. Lurje G, Lenz HJ, (2009) EGFR signaling and drug discovery. Oncology 77: 400-410.
13. Xiong HQ, Abbruzzese JL, (2002) Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Seminars in oncology 29: 31-37.
14. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, et al. (2011) Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 102: 614-621.
15. Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, et al. (2005) Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 65: 11018-11025.
16. Iwasa T, Okamoto I, Suzuki M, Nakahara T, Yamanaka K, et al. (2008) Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clinical cancer research: an official journal of the American Association for Cancer Research 14: 6496-6504.
17. Siddiqa A, Long LM, Li L, Marciniak RA, Kazhdan I, (2008) Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC cancer 8: 129.
18. Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT, et al. (2010) A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochemical pharmacology 79: 1398-1409.
19. Datta SR, Dudek H, Tao X, Masters S, Fu H, et al. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241.
20. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G, (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687-689.
21. Cassell A, Grandis JR, (2010) Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert opinion on investigational drugs 19: 709-722.
22. Mitsudomi T, Yatabe Y, (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. The FEBS journal 277: 301-308.
23. Kolch W, Pitt A, (2010) Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nature reviews Cancer 10: 618-629.
24. Grovdal LM, Stang E, Sorkin A, Madshus IH, (2004) Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Experimental cell research 300: 388-395.
25. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, et al. (2000) Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91: 1204-1209.
26. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ, (2002) Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1: 989-997.
27. Yang L, Dan HC, Sun M, Liu Q, Sun XM, et al. (2004) Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer research 64: 4394-4399.
28. Okano J, Gaslightwala I, Birnbaum MJ, Rustgi AK, Nakagawa H, (2000) Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem 275: 30934-30942.
29. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, et al. (2009) Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clinical cancer research: an official journal of the American Association for Cancer Research 15: 3872-3880.
30. Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, et al. (2011) A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 29: 161-166.
31. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, et al. (2009) Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 27: 4481-4486.
32. Tang H, Shao H, Yu C, Hou J, (2011) Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263. Biochem Pharmacol 82: 1066-1072.
33. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, et al. (2005) Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280: 31182-31189.
34. Liccardi G, Hartley JA, Hochhauser D, (2011) EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer research 71: 1103-1114.
35. Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, et al. (2009) Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One 4: e5933.
36. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, et al. (1999) Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4: 1029-1040.
37. Ahsan A, Hiniker SM, Ramanand SG, Nyati S, Hegde A, et al. (2010) Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res 70: 2862-2869.
38. Pangburn HA, Ahnen DJ, Rice PL, (2010) Sulindac metabolites induce proteosomal and lysosomal degradation of the epidermal growth factor receptor. Cancer Prev Res (Phila) 3: 560-572.
39. Galban S, Duckett CS, (2010) XIAP as a ubiquitin ligase in cellular signaling. Cell death and differentiation 17: 54-60.
40. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, et al. (2004) An IAP-IAP complex inhibits apoptosis. The Journal of biological chemistry 279: 34087-34090.
41. Dohi T, Xia F, Altieri DC, (2007) Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Molecular cell 27: 17-28.
42. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC, (2004) Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. The Journal of clinical investigation 114: 1117-1127.